Search

The SARS‐CoV‐2 pandemic defines the global health tension of our time. There are several continuous efforts to find a definitive cure in this regard. According to some adverse effects and problems of customary SARS‐CoV‐2 disease therapies, bioactive compounds, for example probiotics‐derived metabolites (postbiotics) have been accomplishing supreme importance by investigators for adjuvant cures in patients with SARS‐CoV‐2. Postbiotics inhibit angiotensin‐converting enzyme 2 activity and stimulate the immune system. They also boost the SARS‐CoV‐2 disease treatment effectiveness and reduce its adverse effects in SARS‐CoV‐2 illness patients as a result of antiviral and anti‐inflammatory effects. Furthermore, postbiotics having unique features such as high safety, high shelf life and stability to the gastrointestinal tract can be utilized as hopeful instruments for both adjuvant and inhibition strategies in SARS‐CoV‐2 patients with no earnest unfavourable adverse effects. The concept of postbiotics and their biocompatible characteristics are comprehensively discussed in the present review while highlighting the bilateral relationship between postbiotic biometabolites and respiratory tract infection with a special look at the potential biological role in the inactivation of SARS‐CoV‐2 and reduction of related inflammatory pathways. [ABSTRACT FROM AUTHOR]